

Serial Number: Not yet assigned
Filed: Herewith

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1-48 are currently cancelled.

New Claims 49-59 have been added.

--49. (New) An isolated polypeptide molecule having at least 80% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:2;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:2, lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209620, wherein said polypeptide molecule stimulates the proliferation of T-lymphocytes.

50. (New) The isolated polypeptide molecule of Claim 49 having at least 85% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:2;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:2, lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209620, wherein said polypeptide molecule stimulates the proliferation of T-lymphocytes.

51. (New) The isolated polypeptide molecule of Claim 49 having at least 90% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:2;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:2, lacking its

Serial Number: Not yet assigned
Filed: Herewith

associated signal peptide; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209620, wherein said polypeptide molecule stimulates the proliferation of T-lymphocytes.

52. (New) The isolated polypeptide molecule of Claim 49 having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO:2;
(b) the amino acid sequence of the polypeptide of SEQ ID NO:2, lacking its associated signal peptide; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209620, wherein said polypeptide molecule stimulates the proliferation of T-lymphocytes.

53. (New) The isolated polypeptide molecule of Claim 49 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO:2;
(b) the amino acid sequence of the polypeptide of SEQ ID NO:2, lacking its associated signal peptide; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209620, wherein said polypeptide molecule stimulates the proliferation of T-lymphocytes.

54. (New) An isolated polypeptide molecule comprising:

(a) the amino acid sequence of the polypeptide of SEQ ID NO:2;
(b) the amino acid sequence of the polypeptide of SEQ ID NO:2, lacking its associated signal peptide; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding

Serial Number: Not yet assigned
Filed: Herewith

sequence of the cDNA deposited under ATCC accession number 209620.

55. (New) The isolated polypeptide molecule of Claim 54 comprising the amino acid sequence of the polypeptide of SEQ ID NO:2.

56. (New) The isolated polypeptide molecule of Claim 54 comprising the amino acid sequence of the polypeptide of SEQ ID NO:2, lacking its associated signal peptide.

57. (New) The isolated polypeptide molecule of Claim 54 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209620.

58. (New) A chimeric polypeptide comprising a polypeptide molecule according to Claim 54 fused to a heterologous polypeptide.

59. (New) The chimeric polypeptide of Claim 58, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.--